Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WHR1 | P49842 | 2/20 | 0.50 |
| ▸ | KRAS | P01116 | 1/20 | 0.42 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.42 |
| ▸ | RET | P07949 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | NSD2 | O96028 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 3/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 2/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL295421 | 0.82 | WHR1 (0.52) | WHR1KRASSOS1RETKDR | |
| SCHEMBL369450 | 0.80 | PDE4A (0.59) | WHR1KRASSOS1RETKDR | |
| SCHEMBL5568255 | 0.76 | KIT (0.64) | RETKDREGFRKIT | |
| SCHEMBL27734225 | 0.75 | RET (0.44) | WHR1KRASSOS1RETKDR | |
| SCHEMBL1943805 | 0.74 | PDPK1 (0.48) | WHR1RETKDREGFRPDPK1 | |
| SCHEMBL16502035 | 0.74 | LMNA (0.45) | WHR1KRASSOS1RETKDR | |
| SCHEMBL28098004 | 0.74 | KIT (0.58) | RETKDREGFRKIT | |
| SCHEMBL16502044 | 0.73 | EGFR (0.46) | WHR1KRASSOS1KDRPDE4A | |
| SCHEMBL12621366 | 0.73 | WHR1 (0.40) | WHR1KRASSOS1KDRPDE4A | |
| SCHEMBL1940967 | 0.73 | PDE4A (0.49) | WHR1RETKDRNSD2PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492543-B2 | Method for producing quinazoline derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-07-23 | — | — | US | claimed |
| EP-2189450-B1 | METHOD FOR PRODUCING QUINAZOLINE DERIVATIVE | EISAI R&D MAN CO LTD (JP) | 2011-12-21 | — | — | EP | claimed |
| US-20110152521-A1 | Method for Producing Quinazoline Derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-06-23 | — | — | US | claimed |
| EP-2189450-A1 | METHOD FOR PRODUCING QUINAZOLINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2010-05-26 | — | — | EP | claimed |
| CN-102336717-B | Quinazoline derivatives | EISAI R&D MAN CO LTD | 2013-09-18 | — | — | CN | disclosed |
| US-8530654-B2 | Crystals, amorphous substances or salts of methyl N-[3-(6,7-dimethoxy-2-methylaminoquinazolin-4-yl) phenyl] terephthalamic acid | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-09-10 | — | — | US | disclosed |
| US-8513269-B2 | Preparation for external use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-08-20 | — | — | US | disclosed |
| US-8492543-B2 | Method for producing quinazoline derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-07-23 | — | — | US | disclosed |
| US-8492543-B2 | Method for producing quinazoline derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-07-23 | — | — | US | disclosed |
| CN-101687820-B | Process for producing quinazoline derivative | EISAI R&D MAN CO LTD | 2012-07-25 | — | — | CN | disclosed |
| CN-102532041-A | Process for producing quinazoline derivative | EISAI R&D MAN CO LTD | 2012-07-04 | — | — | CN | disclosed |
| EP-2202229-B1 | NOVEL PREPARATION FOR EXTERNAL USE | EISAI R&D MAN CO LTD (JP) | 2012-03-14 | — | — | EP | disclosed |
| EP-2189450-A1 | METHOD FOR PRODUCING QUINAZOLINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2010-05-26 | — | — | EP | disclosed |
| EP-2189450-A1 | METHOD FOR PRODUCING QUINAZOLINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2010-05-26 | — | — | EP | disclosed |
| CN-101687820-A | Process for producing quinazoline derivative | EISAI R&D MAN CO LTD | 2010-03-31 | — | — | CN | disclosed |
| EP-2123641-A1 | CRYSTAL, AMORPHOUS FORM AND SALT OF METHYL N-Ý3-(6,7-DIMETHOXY- 2-METHYLAMINOQUINAZOLIN-4-YL)PHENYL¨TEREPHTHALAMIC ACID | Eisai R&D Management Co., Ltd. (JP) | 2009-11-25 | — | — | EP | disclosed |
| US-20090062539-A1 | CRYSTALS, AMORPHOUS SUBSTANCES OR SALTS OF METHYL N-[3-(6,7-DIMETHOXY-2-METHYLAMINOQUINAZOLIN-4-YL) PHENYL] TEREPHTHALAMIC ACID | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-03-05 | — | — | US | disclosed |
| WO-2009025238-A1 | METHOD FOR PRODUCING QUINAZOLINE DERIVATIVE | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-02-26 | — | — | WO | disclosed |
| EP-1992622-A1 | 4-(3-BENZOYLAMINOPHENYL)-6,7-DIMETHOXY-2- METHYLAMINOQUINAZOLINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2008-11-19 | — | — | EP | disclosed |
| US-20070299094-A1 | 4-(3-benzoylaminophenyl)-6,7-dimethoxy-2-methylaminoquinazoline derivatives | EISAI R&D MANAGEMENT CO., LTD. | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299094-A1 | 4-(3-benzoylaminophenyl)-6,7-dimethoxy-2-methylaminoquinazoline derivatives | ITCH, HRH4, HRH1 | WHR1 2103/4885KRAS 1088/4885SOS1 1936/4885 |
| US-20090062539-A1 | CRYSTALS, AMORPHOUS SUBSTANCES OR SALTS OF METHYL N-[3-(6,7-DIMETHOXY-2-METHYLAMINOQUINAZOLIN-4-YL) PHENYL] TEREPHTHALAMIC ACID | PDE4A, PDE4B, PDE7A | WHR1 2686/4885KRAS 4838/4885SOS1 3941/4885 |
| US-20110152521-A1 | Method for Producing Quinazoline Derivative | HNMT, AZI2, GNMT | WHR1 4774/4885KRAS 2460/4885SOS1 3927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.